

SARS CoV-2 COVID-19 Antigen Rapid Test Kit



Science&Care




Assay Format	Lateral flow test Immuno- chromatographic in vitro test
Test Type	Qualitative
Instrument	Device-free
Sample Material	Nasopharyngeal, Nasal, Oropharyngeal
Target Antigen	Nucleocapsid (N)
Readout time	15 minutes
Sensitivity	97.54%
Specificity	100.00%


Storage temperature 2-30 °C

Novacheck-Ag Antigen Rapid Test 📃


The Novacheck® SARS-COV-2 NASAL Antigen Rapid Test is an immunochromatographic assay for the qualitative detection of SARS COV 2 nucleocapsid antigen in human nasal swabs. For nasal sampling, the sample is collected from the anterior region of the nose; for nasopharyngeal sampling, the sample is collected from the nasopharynx; and for oropharyngeal, the sample is collected from the oropharynx.




Screening



Pandemic can only be contained by interrupting the transmission of infection. Considering that most transmission is caused by asymptomatic virus carriers, systematic and repeated screening of the population has a very special role. Without screening, we deprive ourselves of the opportunity to prevent further de-escalation.









Clinical Validation

The SARS-COV-2 rapid test kit was performed on 163 nasal swabs collected from symptomatic patients who had symptom onset within 7 days. A limited number of patients with symptom onset for more than 7 days and asymptomatic patients were included in the clinical study (n = 163). The sample size was relatively significant, positive agreement 97.54% (159/163) and negative agreement 100.00% (257/257). The test is designed for professional use.




Genauigkeit: 99,04% (257+159) ÷ (159+0+4+257)





EU common list



The result:

SARS- CoV-2, also known as the Covid-19 virus, causes an acute respiratory infectious disease. The main source of infection is currently people infected with the virus, even those who have an asymptomatic course. According to recent epidemiological studies, the incubation period varies from 1 to 14 days, but mostly from 3 to 7 days.



Eurosurveillance Evaluation

Experts from the Paul Ehrlich Institute, in collaboration with researchers from other institutions, examined a total of 122 COVID-19 antigen rapid tests for sensitivity and thus for their ability to detect the

The quality of the tests varied widely. The Novacheck[®] SARS-CoV-2 Antigen Rapid Test was among 96 rapid antigen tests that met the required criteria; 26 tests did not provide the required sensitivity.









EU common list





Science Care

Science & Care Vertriebs GmbH Südring 59, D-69514 Laudenbach +49 6201 99910 info@sciencecare.de www.sciencecare.de